1 October 2019 in The Breast
7 September 2018 in Breast Cancer
The main purposes of metastatic breast cancer (MBC) treatment are to prolong survival and maintain health-related quality of life (HRQOL). Compliance with the HRQOL assessment can be poor, particularly among patients who receive long-term treatment. One possible solution to overcoming this problem is to engage in real-time home monitoring by having patients report outcomes on their personal electronic devices. The objective of this study was to investigate compliance with HRQOL monitoring from home among MBC patients using the Computer-Based Health Evaluation System (CHES) to collect patient data.
1 January 2017 in ESMO Open
Purpose We investigated the prevalence of hypothyroidism (HT) in patients with breast cancer who received radiation therapy to the supraclavicular (SC) field to evaluate the effect of radiation on thyroid. Methods Between April 2007 and May 2016, consecutive patients with invasive breast cancer who received SC radiation were recruited. Thyroid-stimulating hormone (TSH) and free thyroxine (fT4) were measured between April and August 2016. On the basis of the radiation-planning CT images, thyroid volume was calculated and dose–volume parameters were estimated. The endpoints were the prevalence of HT as determined by high levels of TSH and low levels of fT4 in serum, and the prevalence of subclinical HT, determined by high-serum TSH and normal fT4. Results Among the 68 consecutive patients, 26 were excluded from evaluation (10 patients died, 6 had a history of previous thyroid disease and 10 were lost to follow-up). One (2.4%) and six (14.3%) of these patients had HT and subclinical HT, respectively, with a mean TSH level of 8.27 µU/mL. By univariate analysis, a predictive factor of HT and subclinical HT was a thyroid volume <8 cm3 (OR 6.44, 95% CI 1.14 to 36.6; p=0.043). Multivariate analysis also showed an association between thyroid volume <8 cm3 and HT or subclinical HT (OR 18.48, 95% CI 1.48 to 230.86; p=0.024). Conclusions The prevalence of HT in patients with breast cancer studied was relatively low. Although thyroid volume appeared to be a predictive marker of HT in this cohort, further prospective evaluation is needed.
1 February 2021 in The Breast
Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated with nanoparticle albumin–bound paclitaxel (nab-PTX). We conducted a multicenter randomized controlled study to evaluate the optimal dose of nab-PTX. We compared three different doses of q3w nab-PTX (Standard: 260 mg/m2 [SD260] vs Medium: 220 mg/m2 [MD220] vs Low: 180 mg/m2 [LD180]) in patients with HER2-negative metastatic breast cancer (MBC). Primary endpoint was progression-free survival (PFS). Grade 3/4 neuropathy rates in the three doses were estimated using the logistic regression model. The optimal dose was selected in two steps. Initially, if the hazard ratio (HR) for PFS was 1.33, the inferior dose was excluded, and we proceeded with the non-inferior dose. Then, if the estimated incidence rate of grade 3/4 neurotoxicity exceeded 10%, that dose was also excluded. One hundred forty-one patients were randomly assigned to SD260 (n = 47), MD220 (n = 46), and LD180 (n = 48) groups, and their median PFS was 6.66, 7.34, and 6.82 months, respectively. The HRs were 0.73 (95% confidence interval [CI]: 0.42–1.28) in MD220 vs SD260, 0.77 (95% CI 0.47–1.28) in LD180 vs SD260, and 0.96 (95% CI 0.56–1.66) in LD180 vs MD220. SD260 was inferior to MD220 and was excluded. The estimated incidence rate of grade 3/4 neurotoxicity was 29.5% in SD260, 14.0% in MD220, and 5.9% in LD180. The final selected dose was LD180. Intravenous administration of low-dose nab-PTX at 180 mg/m2 q3w may be the optimal therapy with meaningful efficacy and favorable toxicity in patients with MBC.
28 July 2025 in European Journal of Cancer
The optimal radiotherapy regimen following mastectomy and immediate breast reconstruction remains under active investigation. In particular, the safety of moderate hypofractionation (HF) compared to conventional fractionation (CF) for postmastectomy radiotherapy (PMRT) has not been clearly established. Given the growing adoption of HF in breast cancer treatment, a thorough synthesis comparing complication outcomes is essential to guide clinical practice. A comprehensive search was conducted in Embase, MEDLINE, and Cochrane CENTRAL up to January 10, 2025. Studies comparing HF (2.4-2.7 Gy/fraction) and CF (1.8-2.0 Gy/fraction) in patients undergoing immediate breast reconstruction with PMRT were included. Studies involving partial breast irradiation or accelerated fractionation were excluded. Risk of bias was assessed using RoB 2 and ROBINS-I V2; certainty of evidence was evaluated using GRADE. A random-effects meta-analysis was performed, estimating pooled odds ratios (ORs) with 95 % confidence intervals (CIs). The protocol was registered in PROSPERO (CRD42023471267). Eleven studies (n = 3611), including three randomized controlled trials, were included. HF and CF demonstrated similar risks of major complications (OR: 0.83; 95 % CI: 0.51-1.35; p = 0.45; n = 5). No significant differences were observed for infection, wound dehiscence, or hematoma among photon-based studies. HF was associated with a lower risk of capsular contracture (OR: 0.38; 95 % CI: 0.15-0.99; p = 0.05; n = 5). Only one study evaluated quality of life, reporting no difference in physical well-being. HF offers a safety profile comparable to CF following breast reconstruction and may be preferred due to its reduced treatment burden and a potentially lower risk of capsular contracture.
25 January 2023 in Japanese Journal of Clinical Oncology
PGPRO/QOL research Committee of Japan Clinical Oncology Group
PRO/QOL research Committee of Japan Clinical Oncology Group
+10
Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials.